REPLACEMENT OF RENAL FUNCTION BY DIALYSIS REPLACEMENT OF RENAL FUNCTION BY DIALYSIS A textbook of dialysis Edited by WILLIAM DRUKKER, FRANK M. PARSONS AND JOHN F. MAHER Second, revised and enlarged edition 1986 MARTINUS NIJHOFF PUBLISHERS a member of the KLUWER ACADEMIC PUBLISHERS GROUP DORDRECHT/BOSTON/LANCASTER Distributors for the United States and Canada: Kluwer Academic Publishers, 190 Old Derby Street, Hingham, MA 02043, USA for the UK and Ireland: Kluwer Academic Publishers, MTP Press Limited, Falcon House, Queen Square, Lancaster LA11RN, UK for all other countries: Kluwer Academic Publishers Group, Distribution Center, P.O. Box 322,3300 AH Dordrecht, The Netherlands Book information ISBN-13: 978-0-89838-770-4 e-ISBN-13: 978-94-009-6768-7 DOl: 10.1007/978-94-009-6768-7 First edition 1978 Second, revised and enlarged edition 1983 Second printing 1984 Third printing 1986 (pbk) Library of Congress Cataloging~n-Publication Data Main entry under title: Replacement of renal function by dialysis. Includes bibliographies and index. 1. Hemodialysis. 2. Renal insufficiency--Treatment. I. Drukker, William. II. Parsons, Frank M. III. Maher, John F. (John Francis), 1929- . [DNLM: I. Hemodialy- sis. WJ 378 R425j RC901.7.H45R46 1986 617'.461059 85-25825 ISBN-13: 978-0-89838-770-4 Copyright © 1983 by Martinus Nijhoff Publishers, Dordrecht. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, mechanical, photocopying, recording, or otherwise, without the prior wriH-en permission of the publishers, Martinus Nijhoff Publishers, P.O. Box 163,3300 AD Dordrecht, The Netherlands. It is difficult to say what is impossible, for the dream of yesterday is the hope of to-day and the reality of to-morrow. ROBERT H. GODDARD To Molly, Marjorie and Marge FOREWORD TO THE SECOND EDITION BELDING H. SCRIBNER Since the Foreword to the First Edition was written, problems and limitations, represents a significant step there have been important changes in the dialysis field. toward the future development of new immunothera These developments are well represented in the addi peutic techniques to avoid the progression of glomeru tional material in the revised chapters and in the new lonephritis to chronic renal failure. chapters of the second edition of this book. For the dialysis patient, the most important develop Specifically there has been an increasing interest in ment since the first edition of this book has been the dialyzer re-use (Chapter 15). It is of historical interest recognition by Lundin and colleagues (2) and since con that the technique of dialyzer re-use was first devised, firmed by others (3-5), that control of hypertension can not as a cost saving measure, but to reduce the work prevent the development of accelerated atherosclerosis. load of patients who were rebuilding their Kiil dialyzers The pall of gloom raised by our 1974 publication (6) at home (1). Re-use reduced this task from three times now has been lifted, and the prospects for long term weekly to once every two weeks. survival on dialysis have been greatly enhanced. What Continuous ambulatory peritoneal dialysis (CAPD) emerges now is a whole new set of very difficult prob now has made peritoneal dialysis a more acceptable lems that deal with the more subtle factors which may alternative to hemodialysis. It is my belief, however, interfere with long term survival, such as 30 years of that the ultimate role for CAPD will fall short of the exposure to plasticizers leached from blood tubing, or current enthusiastic projections because of the tedium the possible longer term effects of mild aluminum intox required of the patient by constant surveillance of sterile ication which may result from the use of phosphate bin technique. In that regard, I particularly look forward to ders for half a lifetime (Chapter 42). reading Charles Mion's new chapter 23. Mion and his As I write this Foreword, very little progress has been colleagues have devised a filter system that protects the made with the issue of priorities raised in the Foreword patient from infections that develop because of breaks in to the first edition. The difference now is that increasing sterile technique. This system, if proven successful, fiscal austerity will force the issue sooner than expected should help to lower the current high drop-out rate and, particularly in the United States, we are still as ill among patients on CAPD. prepared as we were in 1977 to cope with this complex Another new development (Chapter 48), the use of situation. The socioeconomic challenges must be met as plasmapheresis to help prevent progression of antiglom vigorously as the medical and technological problems erular basement membrane disease and possibly other have been. conditions to end-stage renal disease, despite its obvious REFERENCES dano C, Friedman EA, Milan, New York NY, Wichtig Edi tore, 1981, p 32 1. Pollard TL, Barnett BMS, Eschbach JW, Scribner BH: A 4. Vincenti F, Amend WJ, Abele J, Feduska NJ, Salvatierra 0 technique for storage and multiple re-use of the Kiil dialyzer Jr: The role of hypertension in hemodialysis-associated and blood tubing. Trans Am Soc Artif Intern Organs 13:24, atherosclerosis. Am J Med 68: 363, 1980 1967 5. Charra B, Ca1emard E, Cuche M, Laurent G: Use of "long 2. Lundin AP, Adler AJ, Feinroth MV: Maintenance hemo dialysis" to control hypertension and prolong survival dialysis. Survival beyond the first decade. JAMA 244: 38, among patients on maintenance hemodialysis. Nephron, (in 1980 press) 3. Scribner BH: The long-term Seattle hemodialysis and trans 6. Lindner A, Charra B, Sherrard D, Scribner BH: Accelerated plant survivors. Proc Third Capri Uremia Con!: Pathobiolo atherosclerosis in prolonged maintenance hemodialysis. N gy of Patients Treatedfor 10 Years or More, edited by Gior- Engl J Med 290:697, 1974 VII FOREWORD TO THE FIRST EDITION BELDING H. SCRIBNER The year was 1942 and William Kolff was hard at work many clinical and other ramifications of dialysis thera perfecting the device that would not only revolutionize py. the treatment of renal failure, but more importantly In 1977, this therapy will cost the United States tax point the way to the development of the entire field of payer nearly one billion dollars as the number of dialysis extracorporeal devices in general and cardiac bypass de patients in the United States soars above 30,000, while vices in particular. the projection of the ultimate number increases from The enormity of the impact that Kolfrs contribution 40,000 to 60,000 and the cost projection to two billion was to have on medicine was revealed retrospectively to per year by 1985. Concurrently, in the United States, the me when I recalled that in that same year, 1942, I was a percentage of patients on home dialysis has dropped second year medical student at Stanford University, tak from a high of 41 % in 1973 to just under IS %. This ing among other things, P.J. Hanzlik's required course in trend away from home dialysis cost the United States pharmacology. I have two memories of that course. One taxpayer an additional 150 million dollars in 1976. In an was the requirement that we students learn to recognize effort to control costs, the United Kingdom has in 64 old time drugs by appearance, smell and taste. For creased the percentage of patients on home care to near better or worse, almost all of the 64 have disappeared ly 70%. In addition, the United Kingdom and perhaps from the scene. The other memory is the more pertinent other Western countries are beginning to exert subtle but one. I can still visualize the scene in the small classroom effective cost control on dialyses by limiting the num in the attic of the old red brick Stanford Lane building at bers of dialysis patients (1). In contrast, in the United Webster and Sacramento Streets. Professor Hanzlik had States in 1977, there is no cost control on dialysis. What a pigeon for a "patient" and had planned a dramatic this contrast means to me is that dialysis is having an demonstration. I can still hear him command one of my impact on Western medicine far beyond its significant fellow students to "Seize the patient!", which the stu impact on the patients, family physicians and staff who dent did in fear and uncertainty as the poor bird strug are directly involved. gled against its fate. Hanzlik then proceeded with great The nature and enormity of this impact began to flair and ceremony to inject some drug intended for become apparent to me in 1962 when magazine writer intravenous use into the poor pigeon, where upon the Shana Alexander came to Seattle to do a story on the bird promptly expired and Hanzlik drove home the artificial kidney. I shall always remember how incredu point that intravenous therapy of any kind was dange lous I was that she did not want to see or hear about the rous and should be avoided at all costs. This" conserva patients whose lives had been saved - no interest there. tive" attitude was quite consistent with that prevailing She wanted to find out all about the "life and death throughout the practice of medicine in that era. If intra committee". As a result, her article on the Seattle Life venous therapy was dangerous, then a device for extra and Death Committee appeared in Life Magazine that corporeal circulation must be an invention of the devil! fall (2) and set off discussion and controversy that have Indeed, for the decade after the first clinical dialyses in persisted to the present (3); indeed, the current British Europe and Canada, acceptance was painfully slow and versus American approach to chronic dialysis is but a often resisted by all the usual techniques of those in dramatic extension to international medicine of the bas power. During the early 60's, we encountered exactly the ic "who shall live" issue that was raised by the Seattle same kind of resistance to the concept of chronic dialy Life and Death Committee. I believe that what has hap sis. But as has happened over and over again in all of pened is that dialysis has greatly accelerated the process science, the heresy of one decade becomes the practice of bringing to the forefront a basic issue in Western of the next - a phenomenon that the young heretics medicine that up to now has been kept hidden. That among the third generation readers of this volume issue is priorities. Can the United States really afford to should not forget. spend two billion dollars per year on dialysis? If not, And so, today Drukker, Parsons and Maher have suc who will decide to curtail expenses, and how will the cessfully undertaken the very difficult task if bringing decision be implemented? Significant curtailment alrea together in one volume all the diverse elements of dial dy is being implemented in the United Kingdom by lim ysis therapy. The size of the volume reflects not only the iting the dialysis population (1). The question is how are magnitude of the interdisciplinary effort that brought they able to "get away with it", and if the real truth about the technical and clinical advances, but also the were known, could they get away with it? IX X Foreword to the first edition To put this issue in a different context, I believe the United States in contrast to 2.1 patients/lOO,OOO popu rapid development of dialysis marks the beginning of lation in Western Europe. the end for unrestrained expansion of expensive medical Dialysis doctors can take comfort in the fact that at technology - just as surely as the energy crisis tells us least the question of efficacy is not an issue with our that unlimited expansion of a petroleum based Western expensive technology. But important and unresolved is civilization is about to come to an end. I believe that the sues nag at our conscience with respect to the cost-ben energy crisis poses the greatest threat to democracy that efit ratio of dialysis. These issues are far too complex to has ever been posed in peacetime because the basic ina be resolved during the life-time of the first generation of bility of the democratic process to cope with decisions readers of this volume and pose the ultimate challenge about priorities in times of crises. Does dialysis and oth to the younger generations. The clinical and technologi er very expensive technology pose a similar threat to cal aspects of dialysis must not remain static at the state medical free enterprise as still practiced mainly in the of the art level described in this volume while the United States? Unless we put our house in order, I demand for costly services increases. Rather, we must believe it does. build on the knowledge reviewed in this book to im Let us take a brief look at another example of costly prove the cost-benefit ratio of our services. Meanwhile, medical technology that already has_overtaken dialysis we function as our technological advances create new in terms of total cost. Coronary by-pass surgery is cur social problems. And so my advice to all three genera rently costing Americans nearly two billion dollars per tions is to try understand and cope with a new respon year. Preston, in a just published critique of the opera sibility that dialysis, because of its high cost, has intro tion (4), points out that not only is its efficacy unproven, duced into the basic doctor-patient relationship. How but he makes a strong case for the point that the eco can each of us fulfill our basic responsibility to our nomic incentives of the free enterprise system rather patients while at the same time doing everything possi than medical efficacy explain why in 1975 the operation ble to reduce the overall cost to society of this very was performed on 28 patients/lOO,OOO population in the expensive treatment? REFERENCES 3. Fox RC, Swazey JP: The courage to fail-A social view of organ transplants and dialysis. Chapters 8, 9 and 10. Univer I. Distribution of nephrological services for adults in Great sity of Chicago Press, 1974 Britain. Report of the Executive Committee of the Renal 4. Preston TA: Coronary by-pass surgery: A critical review. Association. Br. Med J2:903, October 16, 1976 Raven Press, New York, 1977 2. Alexander S: They decide who lives, who dies. Life Maga zine, p. 102, November 9, 1962 PREFACE More than 50 years after Haas' first human dialysis, and second edition by incorporating chapters on its history 40 years after Kolfrs pioneering work, a book on the and on the practical aspects. present state of the art cannot be written by one person: The size of the book has almost doubled, partly by obviously it had to be a multi-authored volume. There using more illustrations. The inclusion of a number of fore some overlap between chapters and even a few con colour reproductions has been made possible by a sup troversies between authors became unavoidable. porting grant * of the National Kidney Foundation of However we deliberately avoided editorial streamlin the Netherlands, which the editors gratefully acknow ing of manuscripts, leaving the authors' personal style ledge. and personal opinions unaltered as much as possible. We considered asking several authors to shorten their This may make the book more vivid to read and may chapters. We resisted this as it would have delayed the sometimes stimulate readers to study a subject in greater publishing date and would possibly have removed much detail from the literature. Additionally, both British and material besides being a painful task for our collea American spellings have been kept because of the inter gues. national nature of the book. To preserve space, though, We are aware that there are some overlaps between the index uses only American spelling. chapters and observant readers may even note some The first edition had to be reprinted within a year of controversies between authors. This, however, may sti initial publication and about one year later the publish mulate further personal study of the literature. ers asked us to undertake the task of preparing a second Finally as the observant reader will notice, the se edition. quence of chapters has been changed. Many chapters In the 5 years since publication of the first edition have been regrouped together in a more logical order. much has changed. Not a single chapter remained unal The editors gratefully acknowledge the work of so tered. All were rewritten rather than simply reviewed many distinguished colleagues, who contributed to this and updated. second edition. The number of authors and co-authors has increased They again wish to thank Dr. Belding H. Scribner, the from 64 to 78, 30 contributing for the first time. The pioneer of chronic dialysis, for writing the Foreword to number of chapters has been increased from 42 to 49, 16 this second edition. being entirely new and written by new authors. We reused the peak 7C diagram of Dr. Jonas Berg We are pleased that so many original contributors strom and Peter Fiirst as a logogram, symbolising the were anxious to participate again and that the newly uraemic toxins to be removed by dialysis and related invited contributors accepted the assignment of writing techniques. their chapters, starting from scratch. Again the editors want to acknowledge the invaluable It is, however, with deep sadness that we have to help of Martinus Nijhoffs staff. In particular we thank record the untimely death of two of our friends and col Mr. Boudewijn F. Commandeur, chief of the Medical leagues. Dr. Arthur Gordon died suddenly in November Division and his secretary Miss Judith van Arem and 1979 and Dr. Reginald G. Mason died in October 1981 Mr. Frans B. van Schaik, without whose technical assis shortly after he had completed updating the chapter on tance the production of the book would have been im thrombogenesis and anticoagulation for this new edi possible. We must pay tribute to the dedication and tion. hard work of our secretaries: Mrs. Mabel Mary Lely, This second edition includes chapters on practical use Amsterdam, The Netherlands, Mrs. Frances Haigh, of anticoagulants, on haemoperfusion, haemofiltration Leeds, UK and Mrs. Barbara Fitzgerald, Bethesda, MD, and plasmapheresis. Obviously, a few of them cover USA. Finally without the tolerance, the support and subjects which belong to fringe areas, not serving re devotion of Molly, Marjorie and Marge the editors' placement of renal function. Nevertheless, they may be work would have been impossible. of interest to our readers. They have one important aspect in common wi~h haemodialysis: they require a Amsterdam, W.D. reliable angioaccess for repeated extracorporeal circula Leeds, F.M.P. tion. Bethesda, Md, J.F.M. Also included are new chapters on ophthalmological March 1983. complications and aluminium intoxication in dialysis patients. Peritoneal dialysis has received more emphasis in this * Grant no C80-279. XI TABLE OF CONTENTS Foreword to the second edition BELDING H. SCRIBNER VII Foreword to the first edition BELDING H. SCRIBNER IX Preface THE EDITORS XI Contributors XVII 1. Introduction THE EDITORS 2. Haemodialysis: a historical review WILLIAM. DRUKKER 3 3. Principles and biophysics of dialysis JOHN A. SARGENT and FRANK A. GOTCH 53 4. Membranes DONALD J. LYMAN .......... . 97 5. Dialysers NICHOLAS A. HOENICH and DAVID N. S. KERR 106 6. Pretreatment and preparation of city water for hemodialysis CHRISTINA M. COMTY and FRED L. SHAPIRO 142 7. The composition of dialysis fluid FRANK M. PARSONS and WILLIAM K. STEWART 148 8. Angioaccess KHALID M. H. BUTT . . . . . . . . . . . . . . 171 9. Extracorporeal thrombogenesis: mechanisms and prevention REGINALD G. MASON (deceased), HANSON Y. K. CHUANG and S. FAZAL MOHAM- MAD ........ 186 10. Practical use of anticoagulants ROBERT M. LINDSAY 201 11. Haemodialysis monitors and monitoring PRAKASH R. KESHA VIAH and STANLEY SHALDON 223 12. Biophysics of ultrafiltration and hemofiltration LEE W. HENDERSON ..... . 242 13. Ultrafiltration and haemofiltration, practical applications EDUARD A. QUELLHORST . . . . . . . . 265 14. The polyacrylonitrile membrane; use in dialysis with the Rhodial system. Use in haemofiltration JEAN-LOUIS FUNCK-BRENTANO and NGUYEN-KHOA MAN ......... 275 15. Multiple use of hemodialyzers NORMAN DEANE and JAMES A. BEMIS 286 16. Hemoperfusion JAMES F. WINCHESTER 305 XIV Table of contents 17. Dialysate regeneration ANTONY J. WING, FRANK M. PARSONS and WILLIAM DRUKKER 323 18. Oral sorbents in uremia ELI A. FRIEDMAN ......... . 341 19. Uraemic toxins JONAS BERGSTROM and PETER FURST 354 20. Regular dialysis treatment (RDT) BARBARA G. DELANO . . 391 2l. Peritoneal dialysis: a historical review WILLIAM DRUKKER 410 22. Peritoneal anatomy and transport physiology KARL D. NOLPH 440 23. Practical use of peritoneal dialysis CHARLES M. MION 457 24. Home dialysis ROSEMARIE A. BAILLOD 493 25. Paediatric dialysis RAYMOND A. DONCKERWOLCKE, CYRIL CHANTLER and MICHEL J.c. BROYER 514 26. Acute renal failure CARL M. KJELLSTRAND, CESAR E. PRU, WILLIAM R. JAHNKE and THOMAS D. DAVIN. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 536 27. Nutrition in dialysis patients REINHOLD K. A. KLUTHE 569 28. Blood pressure control in chronic dialysis patients ROBERT P. WHITE and ALBERT L. RUBIN 575 29. Hyperlipidemia and atherosclerosis in chronic dialysis patients JOHN D. BAGDADE ............ . 588 30. Cardiac complications of regular dialysis therapy CHRISTINA M. COMTY and FRED L. SHAPIRO 595 31. Acute complications associated with hemodialysis CHRISTOPHER R. BLAGG 611 32. Hematologic problems of dialysis patients JOSEPH W. ESCHBACH 630 33. Host defenses and infectious complications in maintenance hemodialysis patients WILLIAM F. KEANE and LEOPOLDO R. RAIJ ......... . 646 34. Dialysis associated hepatitis SHEILA POLAKOFF 659 35. Renal osteodystrophy and maintenance dialysis JACK W. COBURN and FRANCISCO LLACH 679 36. Endocrine changes in patients on chronic dialysis JAMES P. KNOCHEL .......... . 712 37. Neurological aspects of dialysis patients FRANS G. I. JENNEKENS and AAGJE JENNEKENS-SCHINKEL 724 38. Ophthalmological complications associated with haemodialysis BETTINE c.P. POLAK ............ . 742 39. Pharmacological aspects of renal failure and dialysis JOHN F. MAHER ......... . 749 40. Anaesthesia and major surgery in patients with renal failure K. BRIAN SLAWSON ............ . 798 41. Trace metals and regular dialysis ALLEN C. ALFREY and W. RODMAN SMYTHE 804